| VENLAFAXINE has interactions with the following medications (listed by active ingredient) | Interaction Details | Severity |
|
ALMOTRIPTAN MALATE
|
Concomitant use of venlafaxine with serotonergic drugs such as 5-hydroxytryptamine drugs (triptans) may potentially cause a life-threatening serotonergic syndrome. This syndrome is characterized by mental status changes (e.g. agitation, hallucination, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g. nausea, emesis, diarrhea).
|
|
Severe |
|
|
CIMETIDINE
|
Concomitant use of these drugs may increase the plasma concentration of venlafaxine.
|
|
Moderate |
|
|
CITALOPRAM HYDROBROMIDE
|
Concomitant use of venlafaxine with serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs) may potentially cause a life-threatening serotonergic syndrome. This syndrome is characterized by mental status changes (e.g. agitation, hallucination, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g. nausea, emesis, diarrhea).
|
|
Severe |
|
|
CLOZAPINE
|
Concomitant use of these drugs may increase the plasma concentration of clozapine.
|
|
Severe |
|
|
DESIPRAMINE
|
Concomitant use of these drugs may increase the plasma concentration of desipramine.
|
|
Moderate |
|
|
DULOXETINE
|
Concomitant use of venlafaxine with serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs) may potentially cause a life-threatening serotonergic syndrome. This syndrome is characterized by mental status changes (e.g. agitation, hallucination, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g. nausea, emesis, diarrhea).
|
|
Severe |
|
|
ELETRIPTAN HYDROBROMIDE
|
Concomitant use of venlafaxine with serotonergic drugs such as 5-hydroxytryptamine drugs (triptans) may potentially cause a life-threatening serotonergic syndrome. This syndrome is characterized by mental status changes (e.g. agitation, hallucination, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g. nausea, emesis, diarrhea).
|
|
Severe |
|
|
ESCITALOPRAM OXALATE
|
Concomitant use of venlafaxine with serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs) may potentially cause a life-threatening serotonergic syndrome. This syndrome is characterized by mental status changes (e.g. agitation, hallucination, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g. nausea, emesis, diarrhea).
|
|
Severe |
|
|
FLUOXETINE
|
Concomitant use of venlafaxine with serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs) may potentially cause a life-threatening serotonergic syndrome. This syndrome is characterized by mental status changes (e.g. agitation, hallucination, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g. nausea, emesis, diarrhea).
|
|
Severe |
|
|
FLUVOXAMINE MALEATE
|
Concomitant use of venlafaxine with serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs) may potentially cause a life-threatening serotonergic syndrome. This syndrome is characterized by mental status changes (e.g. agitation, hallucination, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g. nausea, emesis, diarrhea).
|
|
Severe |
|
|
FROVATRIPTAN SUCCINATE
|
Concomitant use of venlafaxine with serotonergic drugs such as 5-hydroxytryptamine drugs (triptans) may potentially cause a life-threatening serotonergic syndrome. This syndrome is characterized by mental status changes (e.g. agitation, hallucination, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g. hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g. nausea, emesis, diarrhea).
|
|
Severe |
|
|
HALOPERIDOL
|
Concomitant use of these drugs may increase the plasma concentration of haloperidol.
|
|
Moderate |
|
|